
BEST SCIENCE

FOR THE MOST
NEGLECTED



CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY

Dr Bernard Pécoul, DNDi Executive Director


3 December 2019, 10:00 - 17:00

Auditorium Ivan Pictet, Maison de la Paix, Geneva

DNDi

Drugs for Neglected Diseases *initiative*

Abundant R&D pipeline for HCV in 2015... but many drug candidates abandoned



DNDi Hepatitis C Strategy: 3 pillars



Accelerating the development of **ravidasvir**



with

- Pharma companies
- Governments



Supporting **affordable access to all DAAs**



with

- Pharma companies
- Civil Society organisations
- Governments




Working with health providers to **scale –up treatment**




with

- Primary healthcare doctors
- Non Governmental Organizations

Public Interest R&D partnerships: affordable treatments




Voluntary Licences exclude more than 25 percent of HCV infected people in MICs




DAA's prices depend on IP status and Government leadership


(prices in US\$ per 12 weeks)



Only 5 million people treated in 2013-2017 worldwide



Simplification of HCV model of care will be critical to detect and treat 80% of patients still unaware of their status



THANK YOU FOR YOUR ATTENTION

